Intermittent fasting and its effect on HbA1c is a question increasingly raised in GP surgeries and diabetes clinics across the UK. HbA1c — the standard blood test used to diagnose and monitor type 2 diabetes — reflects average blood glucose over two to three months, making it a key target for dietary interventions. As structured eating patterns such as the 5:2 diet and time-restricted eating gain popularity, understanding whether they can meaningfully reduce HbA1c, who stands to benefit, and where caution is needed is essential for anyone managing blood sugar through lifestyle change.

What Is HbA1c and Why Does It Matter for Blood Sugar Control

HbA1c measures average blood glucose over two to three months and is the primary diagnostic and monitoring tool for type 2 diabetes in the UK, with a result of 48 mmol/mol or above confirming a diagnosis.

HbA1c, or glycated haemoglobin, is a blood test that reflects your average blood glucose levels over the preceding two to three months.^[1][2] When glucose circulates in the bloodstream, it binds to haemoglobin — the protein inside red blood cells — and the resulting compound is measured as a percentage or in millimoles per mole (mmol/mol). Red blood cells have a lifespan of roughly 120 days, so HbA1c provides a reliable long-term snapshot of blood sugar control, though it is weighted towards more recent weeks. This makes it a more informative measure than a fasting glucose test, which only captures a single moment in time.

In the UK, HbA1c is the primary diagnostic and monitoring tool for type 2 diabetes and prediabetes. According to NICE guidelines (NG28):

• Below 42 mmol/mol (6.0%) — considered normal

• 42–47 mmol/mol (6.0–6.4%) — indicates prediabetes or non-diabetic hyperglycaemia

• 48 mmol/mol (6.5%) or above — diagnostic of type 2 diabetes

For people already living with type 2 diabetes, NICE recommends an individualised HbA1c target, commonly 48–53 mmol/mol, to reduce the risk of long-term complications including cardiovascular disease, nephropathy, and retinopathy.^[2][3] Evidence from the UK Prospective Diabetes Study (UKPDS 35) demonstrated that each 11 mmol/mol (1%) reduction in HbA1c is associated with meaningful reductions in microvascular and macrovascular complications, which is why even modest improvements are clinically significant.^[4]

It is important to note that HbA1c is not suitable for diagnosis in all circumstances. NICE advises that it should not be used to diagnose diabetes in children and young people, during pregnancy, in people with suspected type 1 diabetes, in those with acute illness, or where conditions affecting red blood cell turnover are present — such as haemoglobinopathies (e.g., sickle cell disease or thalassaemia), haemolytic anaemia, or iron deficiency anaemia. Certain medicines, including high-dose corticosteroids and some HIV antiretroviral therapies, can also affect HbA1c results. In these situations, alternative tests such as fasting plasma glucose or an oral glucose tolerance test should be used. This is why dietary interventions that may influence HbA1c, such as intermittent fasting, have attracted considerable research interest in recent years.

How Intermittent Fasting May Affect Blood Glucose Levels

Intermittent fasting may lower blood glucose primarily through caloric restriction and weight loss, with additional contributions from improved insulin sensitivity and reduced postprandial glucose spikes.

Intermittent fasting (IF) refers to structured eating patterns that cycle between defined periods of fasting and eating. The most widely studied protocols include the 5:2 diet (eating normally for five days and restricting calories to around 500–600 kcal on two non-consecutive days) and time-restricted eating (TRE), such as the 16:8 method, where food is consumed within an eight-hour window each day.^[8]

Several mechanisms have been proposed to explain how intermittent fasting may lower blood glucose and, consequently, HbA1c. It is important to note that much of this mechanistic evidence comes from early or heterogeneous studies, and the relative contribution of each pathway varies by protocol and individual:

• Reduced insulin secretion during fasting periods may allow insulin sensitivity to improve over time, meaning cells respond more effectively to insulin when it is released.

• Depletion of hepatic glycogen stores during fasting encourages the body to shift towards fat oxidation, reducing reliance on glucose as a primary fuel source.

• Caloric restriction and weight loss, which often accompany IF protocols even when not explicitly intended, are well-established drivers of improved glycaemic control and are likely the primary mediators of HbA1c benefit.

• Reduced postprandial glucose spikes may occur when eating is confined to specific windows, though this effect is protocol-dependent and not consistently demonstrated across studies.

These mechanisms are interconnected. Improved insulin sensitivity reduces fasting glucose, and sustained reductions in fasting glucose over weeks and months will naturally be reflected in a lower HbA1c. The degree of benefit is likely influenced by the specific IF protocol followed, individual metabolic health, and adherence over time. The British Dietetic Association (BDA) Intermittent Fasting Food Fact Sheet provides a useful patient-facing overview of these mechanisms.

What the Clinical Evidence Says About Intermittent Fasting and HbA1c

Clinical evidence shows intermittent fasting produces statistically significant HbA1c reductions in type 2 diabetes, broadly comparable to continuous calorie restriction, though long-term data beyond one year remain limited.

The clinical evidence on whether intermittent fasting lowers HbA1c is growing, though it remains somewhat mixed in terms of the magnitude of effect and study quality. Several randomised controlled trials (RCTs) and systematic reviews have examined IF specifically in people with type 2 diabetes or prediabetes.

A 2022 systematic review and meta-analysis published in Obesity Reviews (Harris et al.) found that intermittent fasting was associated with statistically significant reductions in HbA1c in individuals with type 2 diabetes, with mean reductions ranging from approximately 0.3% to 1.0% (3–11 mmol/mol) depending on the protocol and duration. Time-restricted eating and the 5:2 approach both demonstrated benefit, though direct head-to-head comparisons remain limited.

Importantly, RCTs by Carter and colleagues (2016 and 2018) comparing the 5:2 diet with continuous energy restriction in people with type 2 diabetes found that both approaches produced comparable HbA1c reductions, rather than IF being markedly superior.^[7][8] This suggests that the benefit may be largely mediated through weight loss and overall calorie reduction, rather than the fasting pattern itself. Some researchers argue that fasting-specific metabolic effects — independent of calorie intake — may confer additional benefits, particularly in improving insulin sensitivity, but this remains an area of active investigation.

It is also worth noting that most studies have been conducted over relatively short periods (12–24 weeks), and long-term data on sustained HbA1c reduction beyond one year remain limited. Study populations vary considerably in terms of baseline HbA1c, diabetes duration, medication use, and adherence, which makes it difficult to generalise findings. Risk of bias and heterogeneity across trials should be considered when interpreting effect sizes. Overall, the evidence is promising but not yet definitive, and IF should be considered a complementary strategy rather than a standalone treatment for blood sugar management.

Who May Benefit and Who Should Exercise Caution

Adults with prediabetes or early type 2 diabetes may benefit most, but people on insulin, sulphonylureas, or SGLT2 inhibitors face serious risks and must seek medical advice before fasting.

Intermittent fasting may be particularly beneficial for certain groups. Adults with prediabetes or early type 2 diabetes who are overweight or obese may see meaningful improvements in HbA1c, partly through weight loss and partly through direct metabolic effects. Those who find continuous calorie counting difficult may also find structured eating windows easier to maintain in the long term.

However, IF is not appropriate for everyone, and several groups should exercise significant caution or avoid it altogether:

• People taking insulin or sulphonylureas (such as gliclazide or glimepiride): fasting periods substantially increase the risk of hypoglycaemia (low blood sugar). Any dietary change must be discussed with a GP or diabetes specialist before starting.

• People taking SGLT2 inhibitors (such as dapagliflozin, empagliflozin, or canagliflozin): fasting and low-carbohydrate eating can increase the risk of diabetic ketoacidosis (DKA), including euglycaemic DKA — a serious condition that can occur even when blood glucose appears near-normal. The MHRA has issued specific safety guidance on this risk. Anyone taking an SGLT2 inhibitor must seek medical advice before starting any fasting regimen.

• Individuals with a history of eating disorders: structured restriction can trigger or exacerbate disordered eating behaviours.

• Pregnant or breastfeeding women: caloric restriction during these periods is not recommended.

• People with type 1 diabetes: the interplay between fasting, insulin dosing, and ketone production requires careful medical supervision. There is also an elevated risk of DKA.

• Older adults or those who are underweight: further caloric restriction may worsen nutritional status.

Even in otherwise healthy adults, some people experience side effects during fasting periods, including headaches, fatigue, irritability, and difficulty concentrating — particularly in the first one to two weeks. These often resolve as the body adapts.

Recognising and managing hypoglycaemia: If you experience symptoms of hypoglycaemia — including shakiness, sweating, confusion, palpitations, or dizziness — treat promptly with 15–20 g of fast-acting carbohydrate (for example, 150–200 ml of fruit juice, glucose tablets, or sugary sweets). Recheck your blood glucose after 10–15 minutes and repeat treatment if levels remain low. Always carry a fast-acting glucose source when fasting. If someone is unable to swallow, loses consciousness, or has a seizure, call 999 immediately — do not attempt to give food or drink. Anyone experiencing persistent symptoms, worsening blood sugar control, or signs of DKA (such as nausea, vomiting, abdominal pain, or fruity-smelling breath) should stop fasting and seek urgent medical attention.

NHS and NICE Guidance on Diet-Based Approaches to Blood Sugar Management

NICE recommends structured lifestyle interventions as first-line treatment for type 2 diabetes but does not currently endorse intermittent fasting specifically as a preferred dietary approach.

NICE guidelines emphasise that structured lifestyle interventions — including dietary modification, increased physical activity, and weight management — are first-line strategies for both the prevention and management of type 2 diabetes. NICE NG215 (Type 2 diabetes: prevention in people at high risk) recommends referral to an evidence-based behavioural programme for people with non-diabetic hyperglycaemia, such as the Healthier You: NHS Diabetes Prevention Programme (NHS DPP), which incorporates dietary education and physical activity support.^[10] NICE NG28 (Type 2 diabetes in adults: management) provides guidance on HbA1c targets, monitoring, and dietary approaches for those already diagnosed.

While NICE does not currently endorse a specific dietary pattern (such as intermittent fasting) over others for blood sugar management, it acknowledges that low-calorie diets and low-carbohydrate approaches have an evidence base for improving glycaemic control and supporting remission of type 2 diabetes in appropriate individuals. The DiRECT trial (Lancet, 2018) demonstrated that a structured low-calorie diet can achieve remission in a significant proportion of people with type 2 diabetes, and this evidence underpins the NHS England Type 2 Diabetes Path to Remission Programme (formerly the Low Calorie Diet Programme), which delivers supervised low-energy dietary interventions through NHS services.^[11]

Intermittent fasting, as a dietary strategy, is not explicitly addressed in current NICE guidance, though it may be considered within the broader framework of caloric restriction and lifestyle modification. IF is used by some people to manage their weight and blood sugar, but it is not specifically recommended by NICE or NHS England as a preferred approach. Clinicians should be aware that patients may be self-initiating IF and should proactively discuss medication adjustments — particularly for those on insulin, sulphonylureas, or SGLT2 inhibitors — to ensure patient safety.

Practical Steps for Trying Intermittent Fasting Safely in the UK

Anyone considering intermittent fasting to manage blood sugar should first consult their GP, particularly if taking diabetes medication, and monitor blood glucose regularly throughout.

If you are considering intermittent fasting to help manage your blood sugar or lower your HbA1c, taking a structured and informed approach is essential. The following steps can help you do so safely:

1. Speak to your GP or diabetes care team first. This is especially important if you take any medication for diabetes, blood pressure, or other chronic conditions. Your doctor may need to adjust your medication doses to reduce the risk of hypoglycaemia or other complications during fasting periods. This is particularly important if you take insulin, a sulphonylurea (such as gliclazide or glimepiride), or an SGLT2 inhibitor.

2. Choose a sustainable protocol. For many people in the UK, the 16:8 time-restricted eating approach (for example, eating between 10am and 6pm) is more manageable than full-day fasting. The 5:2 method is also widely used and has a reasonable evidence base. The BDA Intermittent Fasting Food Fact Sheet offers practical guidance on both approaches.

3. Monitor your blood glucose regularly if you have diabetes, particularly when starting out. Keep a record of readings and share them with your healthcare team. Be alert to symptoms of hypoglycaemia, including shakiness, sweating, confusion, and palpitations. If a hypo occurs, treat with 15–20 g of fast-acting carbohydrate, recheck after 10–15 minutes, and repeat if needed.^[2] Always carry a fast-acting glucose source. Call 999 if someone is unconscious or unable to swallow. For NHS guidance on recognising and treating hypoglycaemia, visit the NHS website.

4. Prioritise nutritional quality during eating windows. Fasting does not compensate for a poor diet. Focus on whole grains, vegetables, lean proteins, and healthy fats, in line with NHS Eatwell Guide principles.

5. Set realistic expectations. HbA1c changes gradually — it typically takes at least three months to see a meaningful shift. Consistency and overall lifestyle habits matter more than any single dietary strategy.

6. Report suspected medicine side effects. If you experience any unexpected side effects from your medicines — including after a dose adjustment — you can report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

If you experience persistent side effects, worsening blood sugar control, or feel unwell, contact your GP. Intermittent fasting can be a valuable tool, but it works best as part of a broader, medically supported approach to metabolic health.

Frequently Asked Questions